HOME
COMPANY
COMPANY OVERVIEW
LEADERSHIP TEAM
SCIENCE
PIPELINE
NEWS
PUBLICATIONS
Contacts:
Email
info@nuravax.com
COMPANY OVERVIEW
LEADERSHIP TEAM
NEWS
Company news
In the News
Bloomberg
05.24.2022
PharmaJet Partner, Institute for Molecular Medicine, Launches Clinical Trial for the First in Human Alzheimer’s DNA Vaccine
Learn more
Fierce
01.18.2022
DNA vaccine spurs antibodies against a common Parkinson's target in mice
Learn more
BioSpace
01.12.2022
Oh, Where Vaccines Could Take Us
Learn more
Physical Therapy Products
01.11.2022
NOVEL PREVENTIVE VACCINE FOR PARKINSON’S DISEASE WOULD MOVE INTO HUMAN TRIALS
Learn more
Finance Insider
01.10.2022
Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials
Learn more
BioSpace
11.25.2021
Giving Thanks for Scientific Advances and COVID-19 Relief
Learn more
Finance Insider
11.22.2021
As gene-editing moves mainstream, a pioneer in the field is testing whether it could prevent Alzheimer's
Learn more
Corriere Nazionale
11.14.2021
Alzheimer: passi avanti per lo sviluppo di un vaccino
Learn more
Biogen
11.11.2021
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
Learn more
BioSpace
10.27.2021
Vaccine for Alzheimer’s Could Be on the Horizon
Learn more
Technology Networks
10.25.2021
Developing a Vaccine for Alzheimer’s Disease
Learn more
Alzheimer's News Today
10.18.2021
Nuravax Acquires Rights for MultiTEP Vaccine Platform Tech
Learn more
Press Releases
Cision
03.15.2022
Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Preventive Vaccine for Alzheimer's Disease
Learn more
Cision
01.10.2022
Novel Preventive Vaccine for Parkinson's Disease Would Move into Human Trials
Learn more
Cision
09.29.2021
The Institute for Molecular Medicine Exclusively Licenses MultiTEP, a Universal Vaccine Platform Technology, to New Biotechnology Company Nuravax
Learn more
Cision
11.22.2021
The Institute for Molecular Medicine has Received a Total $7.7M From NIH to Develop a First-of-its-Kind Vaccine Targeting Both Hallmarks of Alzheimer's Disease
Learn more
CONTACT US
© 2022 Nuravax